Medlab Clinical (AU:MDC) has released an update.
Medlab Clinical Ltd has announced its Q4 2024 financial results, highlighting that it is in talks to acquire a business for re-listing on the ASX and expects to begin re-compliance post-transaction. The company reported no cash receipts and a closing cash balance of $110K for the quarter, with outflows relating to corporate expenses for mandatory disclosures and $17K in director fees.
For further insights into AU:MDC stock, check out TipRanks’ Stock Analysis page.
